|
CN103435581B
(zh)
*
|
2004-03-16 |
2015-08-19 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
|
EP1828216B1
(en)
|
2004-12-16 |
2008-09-10 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
CA2595257A1
(en)
*
|
2005-02-23 |
2006-08-31 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
|
|
WO2006108842A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
EP1910390B1
(en)
|
2005-07-27 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
|
|
JP5175191B2
(ja)
*
|
2005-08-30 |
2013-04-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
|
|
ATE491700T1
(de)
*
|
2005-09-08 |
2011-01-15 |
Boehringer Ingelheim Int |
KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-
|
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
|
CA2634701C
(en)
*
|
2005-12-21 |
2014-07-29 |
Decode Genetics Ehf |
Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
|
|
ATE517099T1
(de)
*
|
2006-02-15 |
2011-08-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
JP5384343B2
(ja)
*
|
2006-08-15 |
2014-01-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
|
|
JP5372759B2
(ja)
*
|
2006-09-21 |
2013-12-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
|
|
US8283326B2
(en)
*
|
2006-10-27 |
2012-10-09 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
JP2010508371A
(ja)
|
2006-11-06 |
2010-03-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
|
|
WO2008090210A1
(en)
*
|
2007-01-26 |
2008-07-31 |
Boehringer Ingelheim International Gmbh |
Methods for preventing and treating neurodegenerative disorders
|
|
CA2679310A1
(en)
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
JP5583003B2
(ja)
*
|
2007-04-02 |
2014-09-03 |
セラコス・インコーポレイテッド |
ベンジルグルコシド誘導体およびその用途
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
WO2009026537A1
(en)
|
2007-08-23 |
2009-02-26 |
Theracos, Inc. |
Benzylbenzene derivatives and methods of use
|
|
CA2706018C
(en)
*
|
2007-11-30 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
|
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
|
UA105362C2
(en)
*
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
CN102177147A
(zh)
*
|
2008-08-22 |
2011-09-07 |
泰拉科斯有限公司 |
制备sglt2抑制剂的方法
|
|
AU2009286380B2
(en)
*
|
2008-08-28 |
2011-09-15 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
|
|
CA2736304A1
(en)
|
2008-09-08 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Pyrazolopyrimidines and their use for the treatment of cns disorders
|
|
US20110046076A1
(en)
|
2009-02-13 |
2011-02-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
AU2016213789B2
(en)
*
|
2009-02-13 |
2018-01-18 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
US20110014284A1
(en)
|
2009-02-13 |
2011-01-20 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
JP5896276B2
(ja)
*
|
2009-02-13 |
2016-03-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１型糖尿病、２型糖尿病、耐糖能障害又は高血糖の治療用ｓｇｌｔ−２阻害薬
|
|
GEP20146098B
(en)
*
|
2009-03-31 |
2014-05-27 |
Boehringer Ingelheim Int |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
|
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
|
CA2775961C
(en)
|
2009-09-30 |
2017-11-07 |
Boehringer Ingelheim International Gmbh |
Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
|
DK2486029T3
(en)
*
|
2009-09-30 |
2015-08-24 |
Boehringer Ingelheim Int |
Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
|
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
|
NZ599945A
(en)
|
2009-11-02 |
2014-05-30 |
Pfizer |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
WO2011070592A2
(en)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
|
EP2552442A1
(en)
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
|
PT2595980E
(pt)
|
2010-07-22 |
2014-11-27 |
Gilead Sciences Inc |
Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
|
|
BR112013003097B1
(pt)
|
2010-08-12 |
2021-03-16 |
Boehringer Ingelheim International Gmbh |
6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
|
|
JP2013224263A
(ja)
*
|
2010-08-19 |
2013-10-31 |
Taisho Pharmaceutical Co Ltd |
４−イソプロピルフェニルグルシトール化合物
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
CA2813671A1
(en)
|
2010-11-02 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
|
JP2014512399A
(ja)
*
|
2011-04-25 |
2014-05-22 |
ベイジン・プレリュード・ファーム・サイ・アンド・テック・カンパニー・リミテッド |
ナトリウム依存性グルコース輸送タンパク質阻害剤並びにその調製方法及び使用
|
|
EA201301354A1
(ru)
|
2011-06-03 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
EP2755722B1
(en)
|
2011-09-13 |
2017-05-24 |
Panacea Biotec Ltd. |
Novel sglt inhibitors
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
|
BR112014027884A2
(pt)
|
2012-05-09 |
2017-06-27 |
Boehringer Ingelheim Int |
combinações farmacêuticas para tratamento de distúrbios metabólicos
|
|
PL2981269T3
(pl)
|
2013-04-04 |
2024-02-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Leczenie zaburzeń metabolicznych u zwierząt koniowatych
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
TR201901110T4
(tr)
|
2013-04-05 |
2019-02-21 |
Boehringer Ingelheim Int |
Empagliflozinin terapötik kullanımları.
|
|
DK2986304T3
(da)
|
2013-04-18 |
2022-04-04 |
Boehringer Ingelheim Int |
Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
|
|
WO2015043473A1
(en)
*
|
2013-09-25 |
2015-04-02 |
Sunshine Lake Pharma Co., Ltd. |
Glucopyranosyl derivatives and their uses in medicine
|
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
|
ES2859905T3
(es)
|
2013-12-17 |
2021-10-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
|
|
US10603300B2
(en)
*
|
2014-01-23 |
2020-03-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in canine animals
|
|
ES2811261T3
(es)
*
|
2014-04-01 |
2021-03-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabólicos en animales equinos
|
|
ES2991763T3
(es)
|
2014-09-25 |
2024-12-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de combinación de inhibidores de SGLT2 y agonistas de dopamina para la prevención de trastornos metabólicos en animales equinos
|
|
TWI740546B
(zh)
|
2014-10-29 |
2021-09-21 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
KR20220070057A
(ko)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
|
CN107995862B8
(zh)
|
2015-08-27 |
2021-12-03 |
勃林格殷格翰维特梅迪卡有限公司 |
包含sglt-2抑制剂之液态药物组合物
|
|
PL3349758T3
(pl)
|
2015-09-16 |
2022-09-12 |
Gilead Sciences, Inc. |
Sposoby leczenia zakażeń wirusami arenaviridae
|
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
AU2017357589B2
(en)
|
2016-11-10 |
2023-05-11 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
KR102460968B1
(ko)
|
2017-03-14 |
2022-11-01 |
길리애드 사이언시즈, 인코포레이티드 |
고양이 코로나바이러스 감염의 치료 방법
|
|
SG11201909046XA
(en)
|
2017-04-03 |
2019-10-30 |
Coherus Biosciences Inc |
PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
|
|
JP2020518578A
(ja)
|
2017-05-01 |
2020-06-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
（Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
|
|
CA3077489A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
AU2020323037B2
(en)
*
|
2019-07-26 |
2023-08-03 |
Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. |
SGLTS/DPP4 inhibitor and application thereof
|
|
UY38969A
(es)
|
2019-11-28 |
2021-05-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
|
|
CN118766947A
(zh)
|
2020-01-27 |
2024-10-15 |
吉利德科学公司 |
用于治疗SARS CoV-2感染的方法
|
|
CN118615450A
(zh)
|
2020-02-17 |
2024-09-10 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
|
|
MX2022010748A
(es)
|
2020-03-06 |
2022-09-23 |
Vertex Pharma |
Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
|
|
TWI890963B
(zh)
|
2020-03-12 |
2025-07-21 |
美商基利科學股份有限公司 |
1'-氰基核苷之製備方法
|
|
CN115362004A
(zh)
|
2020-04-06 |
2022-11-18 |
吉利德科学公司 |
1’-氰基取代的碳核苷类似物的吸入制剂
|
|
ES3041698T3
(en)
|
2020-05-29 |
2025-11-13 |
Gilead Sciences Inc |
Remdesivir for the treatment of viral infections
|
|
JP2023531524A
(ja)
|
2020-06-24 |
2023-07-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノヌクレオシド類似体及びその使用
|
|
IL300453A
(en)
|
2020-08-27 |
2023-04-01 |
Gilead Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
JP2024525981A
(ja)
|
2021-07-28 |
2024-07-12 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
|
|
CA3223537A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
|
CA3242880A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
COMBINATION OF OBITECRAPIB AND SGLT2 INHIBITOR
|
|
TW202525810A
(zh)
|
2022-03-02 |
2025-07-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
|
JP2025516857A
(ja)
|
2022-05-25 |
2025-05-30 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
Ｓｇｌｔ－２阻害薬を含む水性医薬組成物
|
|
AU2024233233A1
(en)
|
2023-03-06 |
2025-09-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
KR20250172894A
(ko)
|
2023-04-24 |
2025-12-09 |
뉴암스테르담 파마 비.브이. |
비정질 오비세트라피브 및 sglt2 억제제 조합
|
|
WO2024240633A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
|
|
TW202508593A
(zh)
|
2023-05-24 |
2025-03-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|